340B Drug Pricing Program
We are deeply disappointed the U.S. District Court for the District of Columbia late Friday ruled against the Department of Health and Human Services (HHS) in a lawsuit brought by the Pharmaceutical Research and Manufacturers of America (PhRMA).
Yesterday, the Health Resources and Services Administration (HRSA) published its final rule clarifying the Patient Protection and Affordable Care Act (ACA) provision that excludes orphan drugs for purchase under the 340B drug pricing program
America's hospitals welcome today's announcement that the Health Resources and Services Administration intends to delay the compliance date by which certain hospitals participating in the 340B drug pricing program must meet agency guidance.
Submit Letters to HRSA Outlining Challenges with 340B GPO Notice -- AHA model letter can guide your comments